Association of RNA m7G Modification Gene Polymorphisms with Pediatric Glioma Risk
Table 3
Stratification analysis between WDR4 genotypes and glioma risk.
Variables
rs15736 (cases/controls)
AOR (95% CI)a
a
Protective genotypesb (cases/controls)
AOR (95% CI)a
a
GG
GA/AA
0–4
5
Age, month
<60
112/138
21/36
0.71 (0.39-1.29)
0.256
112/139
21/35
0.73 (0.40-1.34)
0.312
≥60
154/161
25/45
0.58 (0.34-0.995)
0.048
154/162
25/44
0.60 (0.35-1.02)
0.061
Gender
Females
123/123
22/41
0.55 (0.31-0.98)
0.042
123/124
22/40
0.57 (0.32-1.01)
0.055
Males
143/176
24/40
0.72 (0.41-1.25)
0.238
143/177
24/39
0.74 (0.42-1.29)
0.291
Subtypes
Astrocytic tumors
184/299
28/81
0.54 (0.34-0.87)
0.011
184/301
28/79
0.60 (0.35-0.90)
0.016
Ependymoma
50/299
11/81
0.82 (0.40-1.67)
0.575
50/301
11/79
0.84 (0.41-1.71)
0.620
Neuronal and mixed
21/299
4/81
0.73 (0.24-2.19)
0.572
21/301
4/79
0.75 (0.25-2.27)
0.614
Embryonal tumors
10/299
2/81
0.72 (0.15-3.40)
0.673
10/301
2/79
0.74 (0.16-3.53)
0.706
Clinical stages
193/299
31/81
0.58 (0.37-0.92)
0.019
193/301
31/79
0.60 (0.38-0.95)
0.029
73/299
14/81
0.70 (0.37-1.30)
0.257
73/301
14/79
0.72 (0.39-1.35)
0.307
AOR: adjusted odds ratio; CI: confidence interval. aAdjusted for age and gender, omitting the corresponding stratify factor. bProtective genotypes were carriers with rs2156315 CC/CT, rs2156316 CG/GG, rs6586250 CT/TT, rs15736 GA/AA, and rs2248490 CG/GG genotypes.
